Please login to the form below

Not currently logged in
Email:
Password:

IMI appoints new chair of scientific committee

Portugal’s Maria Beatriz da Silva Lima to join EC’s collaborative research group

IMI Maria Beatriz da Silva LimaProf Maria Beatriz da Silva Lima has been elected chair of the Scientific Committee of the Innovative Medicines Initiative (IMI).

Prof da Silva Lima (pictured) of the University of Lisbon in Portugal will lead a 12-strogn committee, which provides strategic scientific advice to the IMI – a public-private partnership between the EC and the industry to improve health innovation in Europe.

The IMI also announced that Prof Markus Perola of Finland's National Institute for Health and Welfare as vice-chair of the Committee.

IMI executive director Michel Goldman said: 'The Scientific Committee represents the voice of the scientific community within IMI, and their input is vital to our success.

“I am looking forward to working with Maria Beatriz da Silva Lima and Markus Perola, and the rest of the committee, to foster open collaboration in pharmaceutical research.'

Prof da Silva Lima described the appointment as a “great honour” and praised the work of the IMI so far, which includes a dementia trials alliance between pharma companies and a research collaboration to discover new antibiotics.

She said: “Thanks to IMI, we have seen an enormous reformulation of the European research environment as well as researchers attitude. This re-thinking of the full drug development process is the most challenging and exciting exercise that I have experienced during my entire working life.

“Finally, there is huge potential to expand the principles underlying IMI to the rest of the world.”

16th January 2014

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Oxford University Press

Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...

Latest intelligence

Five companies 20 for 2020
20 for 2020 – Five pharma companies to watch
As a new decade gets into gear, we take a look at five pharma companies that have a lot riding on 2020...
The growing clinical importance of patient-reported outcomes (PROs)
Traditionally, the success or otherwise of medical treatments has been assessed by mortality or clinical assessments of health. However, patient self-reports of health are increasingly seen as central to the...
Generation Z
The roaring ‘20s and Generation Z
How a new generation will shape pharma comms this decade...

Infographics